BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 18, 2025
See today's BioWorld MedTech
Home
» Therapanacea develops AI solution to quantify the severity of lung damage from COVID-19
To read the full article
sign up for free
or
sign in
.
AI solution for prognosis of COVID-19 pneumonia
Therapanacea develops AI solution to quantify the severity of lung damage from COVID-19
Oct. 12, 2020
By
Bernard Banga
PARIS – A consortium that includes Therapanacea SAS, GE Healthcare France SAS, Orange Healthcare SA, the AP-HP group of 39 hospitals in the Paris region and the French academic society for thoracic imaging has created a database for COVID-19.
BioWorld MedTech
Respiratory
Coronavirus
Diagnostics
Artificial intelligence
Digital health
Europe